Phosphodiesterase-4 inhibition as a therapeutic approach to treat capillary leakage in systemic inflammation

Journal of Physiology

Volumn 590, Issue 11, 2012, Pages 2693-2708

  Schick, Martin Alexander ^a   Wunder, Christian ^a   Wollborn, Jakob ^a   Roewer, Norbert ^a   Waschke, Jens ^b   Germer, Christoph Thomas ^a   Schlegel, Nicolas ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; LIPOPOLYSACCHARIDE; PHOSPHODIESTERASE IV; ROFLUMILAST; ROLIPRAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GAS ANALYSIS; CAPILLARY LEAK SYNDROME; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM; ENZYME INHIBITION; HEMODYNAMICS; INFLAMMATION; LOADING DRUG DOSE; MALE; MEMBRANE STABILIZATION; MESENTERY BLOOD VESSEL; METABOLISM; MICROCIRCULATION; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; VENULE;

AMINOPYRIDINES; ANIMALS; BENZAMIDES; CAPILLARIES; CAPILLARY PERMEABILITY; CYCLIC AMP; CYCLOPROPANES; ENDOTHELIUM, VASCULAR; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MICROCIRCULATION; PHOSPHODIESTERASE 4 INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; ROLIPRAM; VASCULAR DISEASES;

EID: 84861711362     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2012.232116     Document Type: Article

References (57)

1. Adamson RH, Liu B, Fry GN, Rubin LL & Curry FE (1998). Microvascular permeability and number of tight junctions are modulated by cAMP. Am J Physiol Heart Circ Physiol 274, H1885-1894.
2. Adamson RH, Ly JC, Sarai RK, Lenz JF, Altangerel A, Drenckhahn D & Curry FE (2008). Epac/Rap1 pathway regulates microvascular hyperpermeability induced by PAF in rat mesentery. Am J Physiol Heart Circ Physiol 294, H1188-1196.
3. Adamson RH, Zeng M, Adamson GN, Lenz JF & Curry FE (2003). PAF- and bradykinin-induced hyperpermeability of rat venules is independent of actin-myosin contraction. Am J Physiol Heart Circ Physiol 285, H406-417.
4. Baumer Y, Spindler V, Werthmann RC, Bunemann M & Waschke J (2009). Role of Rac 1 and cAMP in endothelial barrier stabilization and thrombin-induced barrier breakdown. J Cell Physiol 220, 716-726.
5. Beckers CM, van Hinsbergh VW & van Nieuw Amerongen GP (2010). Driving Rho GTPase activity in endothelial cells regulates barrier integrity. Thromb Haemost 103, 40-55.
6. Begany DP, Carcillo JA, Herzer WA, Mi Z & Jackson EK (1996). Inhibition of type IV phosphodiesterase by Ro 20-1724 attenuates endotoxin-induced acute renal failure. J Pharmacol Exp Ther 278, 37-41.
7. Bekker AY, Ritter AB & Duran WN (1989). Analysis of microvascular permeability to macromolecules by video-image digital processing. Microvasc Res 38, 200-216.
8. Birukova AA, Liu F, Garcia JG & Verin AD (2004). Protein kinase A attenuates endothelial cell barrier dysfunction induced by microtubule disassembly. Am J Physiol Lung Cell Mol Physiol 287, L86-93.
9. Birukova AA, Zagranichnaya T, Alekseeva E, Bokoch GM & Birukov KG (2008). Epac/Rap and PKA are novel mechanisms of ANP-induced Rac-mediated pulmonary endothelial barrier protection. J Cell Physiol 215, 715-724.
10. Bland JM & Altman DG (1998). Survival probabilities (the Kaplan-Meier method). BMJ 317, 1572.
11. Bogatcheva NV, Zemskova MA, Kovalenkov Y, Poirier C & Verin AD (2009). Molecular mechanisms mediating protective effect of cAMP on lipopolysaccharide (LPS)-induced human lung microvascular endothelial cells (HLMVEC) hyperpermeability. J Cell Physiol 221, 750-759.
12. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A & Beume R (2001). In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 297, 280-290.
13. Chanani NK, Cowan DB, Takeuchi K, Poutias DN, Garcia LM, del Nido PJ & McGowan FX Jr (2002). Differential effects of amrinone and milrinone upon myocardial inflammatory signalling. Circulation 106, I284-289.
14. Cinel I & Dellinger RP (2007). Advances in pathogenesis and management of sepsis. Curr Opin Infect Dis 20, 345-352.
15. Coimbra R, Melbostad H, Loomis W, Porcides RD, Wolf P, Tobar M & Hoyt DB (2006). LPS-induced acute lung injury is attenuated by phosphodiesterase inhibition: effects on proinflammatory mediators, metalloproteinases, NF-κB, and ICAM-1 expression. J Trauma 60, 115-125.
16. Cullere X, Shaw SK, Andersson L, Hirahashi J, Luscinskas FW & Mayadas TN (2005). Regulation of vascular endothelial barrier function by Epac, a cAMP-activated exchange factor for Rap GTPase. Blood 105, 1950-1955.
17. Dauphinee SM & Karsan A (2006). Lipopolysaccharide signalling in endothelial cells. Lab Invest 86, 9-22.
18. De Backer D, Creteur J, Dubois MJ, Sakr Y, Koch M, Verdant C & Vincent JL (2006). The effects of dobutamine on microcirculatory alterations in patients with septic shock are independent of its systemic effects. Crit Care Med 34, 403-408.
19. Deitch EA (2005). Rodent models of intra-abdominal infection. Shock 24(Suppl 1), 19-23.
20. Groesdonk HV, Bauer A, Kreft B, Heringlake M, Paarmann H & Pagel H (2009). Urodilatin and pentoxifylline prevent the early onset of Escherichia coli-induced acute renal failure in a model of isolated perfused rat kidney. Kidney Blood Press Res 32, 81-90.
21. Gross JF & Aroesty J (1972). Mathematical models of capillary flow: a critical review. Biorheology 9, 225-264.
22. Hack CE & Zeerleder S (2001). The endothelium in sepsis: source of and a target for inflammation. Crit Care Med 29, S21-S27.
23. Hiltebrand LB, Krejci V & Sigurdsson GH (2004). Effects of dopamine, dobutamine, and dopexamine on microcirculatory blood flow in the gastrointestinal tract during sepsis and anaesthesia. Anesthesiology 100, 1188-1197.
24. Jacobson JR & Garcia JG (2007). Novel therapies for microvascular permeability in sepsis. Curr Drug Targets 8, 509-514.
25. Koga S, Morris S, Ogawa S, Liao H, Bilezikian JP, Chen G, Thompson WJ, Ashikaga T, Brett J, Stern DM et al. (1995). TNF modulates endothelial properties by decreasing cAMP. Am J Physiol Cell Physiol 268, C1104-C1113.
26. Lee WL & Slutsky AS (2010). Sepsis and endothelial permeability. N Engl J Med 363, 689-991.
27. Lehtonen LA, Antila S & Pentikainen PJ (2004). Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet 43, 187-203.
28. Lin YC, Adamson RH, Clark JF, Reed RK & Curry FR (2012). Phosphodiesterase 4 inhibition attenuates plasma volume loss and transvascular exchange in volume-expanded mice. J Physiol 590, 309-322.
29. Lin YC, Samardzic H, Adamson RH, Renkin EM, Clark JF, Reed RK & Curry FR (2011). Phosphodiesterase 4 inhibition attenuates atrial natriuretic peptide-induced vascular hyperpermeability and loss of plasma volume. J Physiol 589, 341-353.
30. Lugnier C (2006). Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol Ther 109, 366-398.
31. Medzhitov R (2001). Toll-like receptors and innate immunity. Nat Rev Immunol 1, 135-145.
32. Mehta D & Malik AB (2006). Signaling mechanisms regulating endothelial permeability. Physiol Rev 86, 279-367.
33. Nacul FE, Guia IL, Lessa MA & Tibirica E (2010). The effects of vasoactive drugs on intestinal functional capillary density in endotoxemic rats: intravital video-microscopy analysis. Anesth Analg 110, 547-554.
34. Nehls V & Drenckhahn D (1991). Demonstration of actin filament stress fibers in microvascular endothelial cells in situ. Microvasc Res 42, 103-112.
35. Netherton SJ & Maurice DH (2005). Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. Mol Pharmacol 67, 263-272.
36. Patterson CE, Lum H, Schaphorst KL, Verin AD & Garcia JG (2000). Regulation of endothelial barrier function by the cAMP-dependent protein kinase. Endothelium 7, 287-308.
37. Rixen D, Raum M, Bouillon B, Lefering R & Neugebauer E (2001). Base deficit development and its prognostic significance in posttrauma critical illness: an analysis by the trauma registry of the Deutsche Gesellschaft fur unfallchirurgie. Shock 15, 83-89.
38. Russell JA (2006). Management of sepsis. Minerva Med99, 431.
39. Schick M, Isbary T, Schlegel N, Brugger J, Waschke J, Muellenbach R, Roewer N & Wunder C (2010). The impact of crystalloid and colloid infusion on the kidney in rodent sepsis. Intensive Care Med 36, 541-548.
40. Schlegel N, Baumer Y, Drenckhahn D & Waschke J (2009). Lipopolysaccharide-induced endothelial barrier breakdown is cAMP dependent in vivo and in vitro. Crit Care Med 37, 1735-1743.
41. Schlegel N, Burger S, Golenhofen N, Walter U, Drenckhahn D & Waschke J (2008). The role of VASP in regulation of cAMP- and Rac 1-mediated endothelial barrier stabilization. Am J Physiol Cell Physiol 294, C178-C188.
42. Schlegel N & Waschke J (2009a). Impaired cAMP and Rac 1 signaling contribute to TNF-α-induced endothelial barrier breakdown in microvascular endothelium. Microcirculation 16, 521-533.
43. Schlegel N & Waschke J (2009b). VASP is involved in cAMP-mediated Rac 1 activation in microvascular endothelial cells. Am J Physiol Cell Physiol 294, C178-C188.
44. Schmidt EP, Damarla M, Rentsendorj O, Servinsky LE, Zhu B, Moldobaeva A, Gonzalez A, Hassoun PM & Pearse DB (2008). Soluble guanylyl cyclase contributes to ventilator-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol 295, L1056-L1065.
45. Seybold J, Thomas D, Witzenrath M, Boral S, Hocke AC, Brger A, Hatzelmann A, Tenor H, Schudt C, Krll M, Schtte H, Hippenstiel S & Suttorp N (2005). Tumor necrosis factor-α-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood 105, 3569-3576.
46. Shinoda T, Smith CE, Khairallah PA, Fouad-Tarazi FM & Estafanous FG (1991). Effects of propranolol on myocardial performance during acute normovolemic hemodilution. J Cardiothorac Vasc Anesth 5, 15-22.
47. Sielenkamper AW, Meyer J, Kloppenburg H, Eicker K & Van Aken H (2001). The effects of sepsis on gut mucosal blood flow in rats. Eur J Anaesthesiol 18, 673-678.
48. Spindler V, Schlegel N & Waschke J (2010). Role of GTPases in control of microvascular permeability. Cardiovasc Res 87, 243-253.
49. Tofovic SP, Zacharia LC, Carcillo JA & Jackson EK (2000). Inhibition of cytokine release by and cardiac effects of type IV phosphodiesterase inhibition in early, profound endotoxaemia in vivo. Clin Exp Pharmacol Physiol 27, 787-792.
50. Trzeciak S, Dellinger RP, Chansky ME, Arnold RC, Schorr C, Milcarek B, Hollenberg SM & Parrillo JE (2007). Serum lactate as a predictor of mortality in patients with infection. Intensive Care Med 33, 970-977.
51. Vandenbroucke E, Mehta D, Minshall R & Malik AB (2008). Regulation of endothelial junctional permeability. Ann N Y Acad Sci 1123, 134-145.
52. Ware LB & Matthay MA (2000). The acute respiratory distress syndrome. N Engl J Med 342, 1334-1349.
53. Waschke J, Baumgartner W, Adamson RH, Zeng M, Aktories K, Barth H, Wilde C, Curry FE & Drenckhahn D (2004a). Requirement of Rac activity for maintenance of capillary endothelial barrier properties. Am J Physiol Heart Circ Physiol 286, H394-H401.
54. Waschke J, Drenckhahn D, Adamson RH, Barth H & Curry FE (2004b). cAMP protects endothelial barrier functions by preventing Rac-1 inhibition. Am J Physiol Heart Circ Physiol 287, H2427-H2433.
55. Waschke J, Drenckhahn D, Adamson RH & Curry FE (2004c). Role of adhesion and contraction in Rac 1-regulated endothelial barrier function in vivo and in vitro. Am J Physiol Heart Circ Physiol 287, H704-H711.
56. Witzenrath M, Gutbier B, Schmeck B, Tenor H, Seybold J, Kuelzer R, Grentzmann G, Hatzelmann A, van Laak V, Tschernig T, Mitchell TJ, Schudt C, Rosseau S, Suttorp N & Schutte H (2009). Phosphodiesterase 2 inhibition diminished acute lung injury in murine pneumococcal pneumonia. Crit Care Med 37, 584-590.
57. Wunder C, Brock RW, McCarter SD, Bihari A, Harris K, Eichelbronner O & Potter RF (2002). Inhibition of haem oxygenase activity increases leukocyte accumulation in the liver following limb ischaemia-reperfusion in mice. J Physiol 540, 1013-1021.